ADHD: New pharmacological treatments on the horizon

Journal of Developmental and Behavioral Pediatrics

Volumn 27, Issue 5, 2006, Pages 410-416

  López, Frank A ^a,b  

^a Children's Development Center   (United States)

^b Children's Developmental Center   (United States)

Author keywords

Attention deficit hyperactivity disorder (ADHD); Methylphenidate transdermal system; Nonstimulants; Stimulants

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; DEXAMPHETAMINE; DEXEDRINE SPANSULE; DEXMETHYLPHENIDATE; FOCALIN XR; GUANFACINE; LISDEXAMFETAMINE; METHYLIN ER; METHYLPHENIDATE; MODAFINIL; UNCLASSIFIED DRUG;

ACADEMIC ACHIEVEMENT; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DEATH; DECREASED APPETITE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GROWTH RETARDATION; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; IRRITABILITY; MOOD DISORDER; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; STOMACH PAIN; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; FORECASTING; HUMANS;

EID: 33750091053     PISSN: 0196206X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004703-200610000-00008     Document Type: Review

References (58)

1. Goldman LM, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA. 1998;279:1100-1107.
2. American Association of Pediatrics. Clinical practice guidelines: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105:1158-1170.
3. Mannuzza S, Klein R, Bonagura N, et al. Hyperactive boys almost grown up: replication of psychiatric status. Arch Gen Psychiatry. 1991;48:77-83.
4. Zametkin A, Ernst M. Problems in the management of attention-deficit/ hyperactivity disorder. N Engl J Med. 1999;340:40-46.
5. Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin N Am. 2000;9:711-726.
6. Pliszka S. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder in children and adolescents. J Clin Psychiatry. 1998;59(suppl 7):50-58.
7. Spencer T, Biederman J, Wilens T. Attention-deficit/hyperactivity disorder and comorbidity. Pediatric Clin North Am. 1999;46:915-927.
8. Leibson C, Long K. Economic implications of attention-deficit/ hyperactivity disorder for healthcare systems. Pharmacoeconomics. 2003;21:1239-1262.
9. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996;35(4):409-432.
10. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl 10):85S-121S.
11. Abikoff H, Hechtman L, Klein RG, et al. Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43:820-829.
12. Hechtman L, Abikoff H, Klein RG, et al. Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43:812-819.
13. MTA Cooperative Group. Fourteen month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry. 1999;56:1073-1086.
14. Olfson M, Gameroff M, Marcus SC, et al. National trends in the treatment of attention-deficit/hyperactivity disorder. Am J Psychiatry. 2003;160:1071-1077.
15. Connors CK, March J, Frances A, et al. Treatment of attention-deficit/ hyperactivity disorder. Expert consensus guideline series. J Atten Disord. 2001;4(suppl 1):S1-S128.
16. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:1033-1044.
17. Frankel F, Cantwell D, Myatt R, et al. Do stimulants improve self-esteem in children with ADHD and peer problems? J Child Adolesc Psychopharmacol. 1999;9:185-194.
18. Elia J, Borcherding BG, Rapoport JL, et al. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. 1991;36:141-155.
19. Safer D, Allen R, Barr E. Depression of growth in hyperactivity children on stimulant drugs. N Engl J Med. 1972;287:217-220.
20. Loney J, Whaley-Klahn M, Ponto LB, et al. Predictors of adolescent height and weight in hyperkinetic boys treated with methylphenidate [proceedings]. Psychopharmacol Bull. 1981;17:132-134.
21. Vincent J, Varley C, Leger P. Effects of methylphenidate on early adolescent growth. Am J Psychiatry. 1990;147:150-152.
22. Zeiner P. Body growth and cardiovascular function after extended treatment (1.75 years) with methylphenidate in boys with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol. 1995;5:129-138.
23. Spencer T, Biederman J, Harding M, et al. Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry. 1996;35:1460-1469.
24. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762-769.
25. Faraone SV, Biederman J, Monuteaux M, et al. Long-term effects of extended-release mixed amphetamine salts treatment of attention-deficit/ hyperactivity disorder on growth. J Child Adolesc Psychopharmacol. 2005;15:191-202.
26. Biederman J, Faraone SV, Monuteaux MC, et al. Growth deficits and attention-deficit/hyperactivity disorder revisited: impact of gender, development and treatment. Pediatrics. 2003;111:1010-1016.
27. Wilens T, Faraone S, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179-185.
28. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:E83.
29. Braun DL, Dulit RA, Adler DA, et al. Attention-deficit/hyperactivity disorder in adults: clinical information for primary care physicians. Primary Psychiatry. 2004;11:56-65.
30. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896-1901.
31. Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40:180-187.
32. Spencer TJ, Newcorn JH, Kratochvil CJ, et al. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/ hyperactivity disorder. Pediatrics. 2005;116:e74-e80.
33. Donnelly M, Zametkin A, Rapoport JL, et al. Treatment of childhood hyperactivity with desipramine: plasma drug concentrations, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther. 1986;39:72-81.
34. Biederman J, Baldessarini R, Wright V, et al. A double-blind placebo controlled study of desipramine in the treatment of ADD: I: Efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28:777-784.
35. Barrickman L, Perry P, Allen AJ, et al. Buproprion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:649-657.
36. Conners CK, Casat CD, Gualtieri CT, et al. Buproprion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996;35:1314-1321.
37. Hunt R, Minderaa R, Cohen DJ. Clonidine benefits children with attention-deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Adolesc Psychiatry. 1985;24:617-629.
38. Hunt R, Arnsten A, Asbell MD. An open trial of guanfacine in the treatment of attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;35:3-4.
39. Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7:106-113.
40. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:1551-1559.
41. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention-deficit/hyperactivity disorder. Am J Psychiatry. 2001;158:1067-1074.
42. Novartis Pharmaceuticals Corporation. 2005. Focalin XR Prescribing Information.
43. NRP104 web page. New River Pharmaceuticals website. Available at: http://www.nrpharma.com/products/NRP104.htm. Accessed December 21, 2005.
44. Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry. 2001;40:230-235.
45. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible dose study. Pediatrics. 2005;116:e777-e784.
46. Rugino T, Samsock T. Modafinil in children with attention deficit hyperactivity disorder. Pediatr Neurol. 2003;29:136-142.
47. Novartis Pharmaceuticals Corporation. Ritalin and Ritalin SR prescribing information, 2004.
48. Novartis Pharmaceuticals Corporation. Ritalin LA prescribing information, 2004.
49. ALZA Corporation. Concerta prescribing information, 2005.
50. Celltech Pharmaceuticals. Metadate CD prescribing information, 2003.
51. Mallinckrodt Pharmaceuticals. Methylin prescribing information, 2000.
52. Novartis Pharmaceuticals Corporation. Focalin prescribing information, 2001.
53. Shire Pharmaceuticals. Adderall XR prescribing information, 2005.
54. SmithKline Beecham Pharmaceuticals. Dexedrine prescribing information, 1998.
55. Eli Lilly and Company. 2005. Strattera prescribing information.
56. Reeves G, Schweitzer J. Pharmacological management of attention-deficit hyperactivity disorder. Expert Opin Pharmacother. 2004;5:1313-1320.
57. Spencer T, Biederman J. Non-stimulant treatment for attention-deficit hyperactivity disorder. J Atten Disord. 2002;6(suppl 1):S109-S119.
58. Wolraich ML, Doffing MA. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs. 2004;18:243-250.